
ã¯ã¯ãã³ã¯ãã³ãããã¯ãçµããããã¯ãã ã£ããéå°ãªæ»äº¡æ°ãç©èªããã®
å èšäºã¯ãã¡ããã/Click here to read the original article.
çŸå®ã«ã¯ã2021幎ã®COVID-19ã¯ã¯ãã³é ååŸãææãšéå°æ»äº¡ã®æ³¢ã¯ç¶ããç±³åœã§ã¯2åºŠã®æ·±å»ãªæ³¢ãç¶ããç¿å¹Ž1ææ«ã«åã³ããŒã¯ã«éããã
èïŒãã€ã±ã«ã»ãã ãªã³ãœã³
çŸåšé²è¡äžã®ãã³ãããã¯æä»£ã®æŽå²ãèªãäžã§ãæ»äº¡çã»ã©éèŠãªãã®ã¯ãªãã
å£®å€§ãªæŠç¥ïŒåã«ãè¿°ã¹ãããã«ã壮倧ã§ãæŠç¥çã§ããªãã£ããïŒã¯ããã¯ã¯ãã³ãå ¥æå¯èœã«ãªããŸã§ ãã®æ«å®æªçœ®ãšããŠãåœå šäœã®äººå£ãå°éããããšã ã£ãã
ããã¯ãSARS-CoV-2ã®ãããªãŠã€ã«ã¹ã«ééããããšããªãããã誰ãããã«å¯Ÿããæ¢åã®å ç«ãæã£ãŠããªããšããçç±ã§ãå šãæ°ããïŒãããŠå šã蚌æãããŠããªãïŒãŠã€ã«ã¹ãæã¡è² ããããã®æ¬æ°ãªæŠç¥ã§ãã£ãã
SARS-CoV-2ã¯ãããã€ãã£ãŒãèªã®ãã®è«æã«ããã°ãã²ãã é åã®çŽ79ïŒ ãå ±æããè¿çžã®SARSã«ã¡ãªãã§åœåãããã
SARS-CoV-2ã¯ã³ãããŠã€ã«ã¹ã®ã¯ã©ã¹ã¿ãŒã«å±ããŠãããå¥ã®ããã€ãã£ãŒãèªã®è«æã§ã¯ã颚éªãŠã€ã«ã¹ãå«ããããã®ãŠã€ã«ã¹ãšã®äº€å·®åå¿æ§ã®çšåºŠã«ã€ããŠè«ããŠãããå€å°ç®æ°ãããã®ã§ã¯ããããç¹å¥ãªãã®ã§ã¯ãªãã
ãããã£ãŠãæ¿çç«æ¡è ãã¡ã¯ãSARS-CoV-2ãæ¥µç«¯ãªæ»äº¡çããããããšãã2020幎åé ã®äž»åŒµã«å¯ŸããŠæççã§ããã¹ãã ã£ãã
ãã®ããšã¯ããã®ãããªã¬ãã«ã®æ»äº¡çãçºçããªãã£ãããã«ã倧æŠç¥ãæåãããšãã䞻匵ã«ã圱é¿ãåãŒãããããã®ãããªããšãèµ·ãããªãã®ã§ããã°ãç§ãã¡ã¯ãã®ãããªäºæ ããæãããå¿ èŠã¯ãªãã£ãã®ã§ããã
ã¯ã¯ãã³ã®é åã¯ããã³ãããã¯ã®çµçããããããã¯ãã ã£ããã¯ã¯ãã³ã®èšåºè©Šéšã§ã¯ãçåæ§ææã90ïŒ ä»¥äžæžå°ãããããšãã§ãããšãããã
éå£ã¬ãã«ã§ã¯ãããã¯èŸ»è€ãåããªãããã90ïŒ ä»¥äžã®ææãã¯ã¯ãã³æ¥çš®ã«ãã£ãŠäºé²ããã2023幎5ææ«ãŸã§ã«2å7000äžäººïŒç·äººå£çŽ3å4000äžäººã®ãã¡ïŒã®ç±³åœäººãã¯ã¯ãã³æ¥çš®ãåãããšãããããããŒã¿ã§èŠãç§ãã¡ã®äžçãã«ããã°ããããŸã§ã«1å人以äžã®ææè ã確èªãããã®ã¯ãªããïŒ
ã¯ã¯ãã³æªæ¥çš®ã®1å7000äžäººã®ãã¡ã1å人è¿ããææè ã ã£ããšã¯ä¿¡ããããªããç¹ã«ãã¯ãªãŒãã©ã³ãã»ã¯ãªããã¯ã®ç ç©¶ã«ããã°ãå¹³åããŠäºé²æ¥çš®ãåããã»ã©ææããå¯èœæ§ãé«ããªãããšã瀺ãããŠããïŒ

ææçãæžå°ããã°æ»äº¡çãæžå°ãããšèããããŠãããïŒãããã«ããããã¯ãªããªãã£ãããã ïŒãèšåºè©Šéšã§ã¯ã¯ã¯ãã³æ¥çš®çŸ€ãšãã©ã»ã矀ãšã®éã«æ»äº¡çã®å·®ã¯èŠãããªãã£ãã
ãªãŒãœããã¯ã¹ãªæåŒã¯ãèšåºè©Šéšã®æ¯éå£ãåå倧ãããªãã£ããããéããæ€åºããã®ã«ååãªæ€åºåããªãã£ããšãããã®ã§ããã
ããããåãæå³ã§ãç§ãã¡ã¯æ¬¡ã®ãããªçµè«ãå°ãåºãæš©å©ãããïŒèšåºè©Šéšã¯ãæ»äº¡çãæžå°ãããã¯ã¯ãã³ã®èœåãå®èšŒããªãã£ãã
å質ä¿èšŒã®ä»äºã§ã¯ãå®éã®çµæãšäž»åŒµãããããšãæ¯èŒããããšã§ãä»å ¥ãããã°ã©ã ã®æåãè©äŸ¡ããã
çŸå®ã«ã¯ã2021幎ã®ã¯ã¯ãã³é ååŸãææãšéå°æ»äº¡ã®æ³¢ã¯ç¶ããç±³åœã§ã¯2åºŠã®æ·±å»ãªæ³¢ãç¶ããç¿å¹Ž1ææ«ã«åã³ããŒã¯ã«éããã
ããŒã¯ã¯æžå°åŸåã«ãã£ããããã³ãããã¯ã®éçšã§äºæ³ããããããªãã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ã®çµæãšããŠãã®åŸåãå€åããããšã¯æããã§ã¯ãªãã
åŸæ¥ã®åžžèã§ã¯ãã¯ã¯ãã³ã¯å šäœçãªææã¬ãã«ã¯äœäžãããªãã£ããããããªãããCOVID-19ã«ããå ¥é¢ãæ»äº¡ã®ã¬ãã«ã¯äœããã®åœ¢ã§äœäžããããšèããããã
ç¹°ãè¿ãããã¯ã¯ãã³æ¥çš®ãææäºé²ã«äžååã§ãããªãããç æ°ã®æžå°ã«æåãããšã¯èããããªãã
ãã®ãããªæåã®äž»åŒµã«ã¯ç¢ºãã蚌æ ããªãã
æè¿çºè¡šãããæ°å€ãã®è«æã¯ã倧æŠç¥ãããŸããããªãã£ãããšãç€ºãæ±ºå®çãªèšŒæ ã§ããããšããã®ããéåžžããã®æŠç¥ã¯æåã ã£ããšçµè«ã¥ããããããã§ããã
ããããããŒã¿ã¯æãšããŠç°ãªãç©èªãèªããããã¯èè ã«åããããããšã瀺ããŠããã圌ãã®ããŒã¿ã¯åœŒãã®ç©èªãããä¿¡é Œã§ããããšãããã
äŸãã°ãç±³åœé圹è»äººå¥åº·ç®¡çå±ïŒU.S. Veterans Health AdministrationïŒã®æ£è ã察象ãšããBajemaãã®ç ç©¶ã§ããã圌ãã¯ããçµè«ã¥ããŠããïŒ
ããã®ã³ããŒãç ç©¶ã§ã¯ã2022幎ãã2023幎ã®ã·ãŒãºã³ã§ã¯ãSARS-CoV-2ãžã®ææã¯ãã€ã³ãã«ãšã³ã¶ãRSVãããé節ãªçŸæ£è»¢åž°ãšé¢é£ããŠãããã2023幎ãã2024幎ã®ã·ãŒãºã³ã§ã¯ããã®å·®ã¯ããã»ã©é¡èã§ã¯ãªãã£ãã
ãRSVã¯äž¡ã·ãŒãºã³ãšã軜çã§ãã£ãããCOVID-19ã¯é·ææ»äº¡çãé«ãã£ããã¯ã¯ãã³æ¥çš®ã«ããéç床ãšé·ææ»äº¡çã®å·®ã¯æžå°ããã
ããã¯æ±ºå®çã§ã¯ãªãã ãããïŒ
ãããããã®çµè«ã¯å³2Aã«èŠçŽãããããŒã¿ã«åºã¥ããŠããïŒ

ãã®æ°åãããããšãCOVID-19ã®180æ¥éã®æ»äº¡çãããæ·±å»ã§ãã£ãããšã¯æåéãäºå®ã§ãããããã®å·®ã¯1ïŒ æªæºã§ãã£ããCOVID-19ã¯100幎ã«äžåºŠã®ãã³ãããã¯ã§ãããã€ã³ãã«ãšã³ã¶ãããåçã«å±éºã§ãå šäžçãéåžžäºæ ã«é¥ããå¿ èŠããã£ãã
ã€ã³ãã«ãšã³ã¶ããæ»äº¡çã1ïŒ ä»¥äžããé«ããªãç æ°ã§ãããã¯æ£åœåã§ããã®ã ãããïŒå€ãã®ã¡ãã£ã¢ã¯ãCOVID-19ãã€ã³ãã«ãšã³ã¶ãšåããããªçŸç è² æ ããããããšãã䞻匵ãå²ç¬ããŠããããæãçµã€ã«ã€ããããã«å¹æµããããšã蚌æãããã
ã¯ã¯ãã³æ¥çš®ã¯ã©ã®çšåºŠåœ¹ã«ç«ã£ãã®ã ãããïŒå³2ã¯COVID-19æ£è ã®æ¯èŒã§ããã

ã€ãŸããæ éã«éžæãããåŠçãããéšåéå£ã®éšåéå£ã«åºã¥ããè«æã§ã¯ãã¯ã¯ãã³æ¥çš®è ã¯180æ¥éã§1ïŒ ã®ååã®å·®ãã€ããããã®ã§ãããããããã¹ããªã®ã ãããïŒçµ±èšçã«ææãªã®ã ãããïŒ
ããåœã®å šäººå£ã«ãããéå°æ»äº¡çã«åºã¥ããè«æã§ããã°ãæ»äº¡çã®COVID-19ãžã®åž°å±ã®ã°ãã€ãã詊éšéå£ã®éžææ§ã«ãã£ãŠåŒãèµ·ããããæ¹æ³è«çåé¡ãé¿ããããšãã§ããã
泚ç®ãã¹ãã¯Dahlãã«ããæè¿ã®ãã¬ããªã³ãã§ããïŒ 2021-20幎ã®ãã«ãŠã§ãŒã®æäººã«ãããCOVID-19 mRNAã¯ã¯ãã³æ¥çš®ãšå šæ»å æ»äº¡çïŒéå£ããŒã¹ã®ã³ããŒãç ç©¶ã
圌ãããæ±ºãŸãã®çµè«ã«éããŠããïŒ ãã¯ã¯ãã³æ¥çš®è ã¯ããã«ãŠã§ãŒã«ããã2021-2023幎ã®å šæ»å æ»äº¡çãäœãã£ãã
ããããç¹°ãè¿ãããããŒã¿ã¯ãã®çµè«ãã©ã®ããã«è£ä»ããŠããã®ã ãããïŒ

ç·å¥³ã®ããŒã¿ã«æ³šç®ããå³ããå·Šã«èªããšã10äžpyåœããã®æ»äº¡è æ°ã¯ãæ»äº¡è ããŸãã§ãã£ãã¯ãã®è¥å¹Žå±€ãé€ããå幎霢局ã§çå®ã«å¢å ããŠããã
å¯Ÿç §çã«ãæé«éœ¢å±€ïŒ65æ³ä»¥äžïŒã§ã¯ãç¡æ¥çš®ã§ã¯3.40人ã1ïœ2åæ¥çš®ã§ã¯7.25人ã3åä»¥äžæ¥çš®ã§ã¯19.21人ãšå¢å ããŠããã
人幎ãããã®æ»äº¡æ°ãšã¯éæ¹åã®çœ¹æ£çæ¯ãå°ãåºãããã«ã圌ãã¯ã©ã®ãããªäžæçãªçµ±èšããžãã¯ã䜿ã£ãã®ã ãããïŒãããŠããªã圌ãã¯ãã®ããšã説æããªãã®ã ãããïŒ
æ¬æã®åŸãã®æ°åãçŽ çŽã«èªãã°ããã«ãŠã§ãŒã§ã¯ãã®æéãã¯ã¯ãã³æ¥çš®è ã®å šæ»å æ»äº¡çã¯ã¯ã¯ãã³æªæ¥çš®è ã®å°ãªããšã2åã§ãã£ãããããã圌ãã¯éã®çµè«ãåºããã
ã€ãŸããç§ãã¡ãç§åŠè ã«ãŸãèŠæ±ããªããã°ãªããªãã®ã¯ãããŒã¿ã«ãã£ãŠæç¢ºã«è£ä»ããããçµè«ãåºãããšãªã®ã ïŒ
ã¯ã¯ãã³æ¥çš®ã«é¢ããè«æã¯ã確蚌ãã€ã¢ã¹ã«ãã£ãŠæ±ºå®çã«åŒ±äœåããŠãããèè ãã¡ã®ã¯ã¯ãã³æ¥çš®ã«å¯Ÿãã信念ã®åŒ·ãã¯ãããšãå察ã®ããŒã¿ã§ãã£ãŠããéåžžãã¹ãŠã®ããŒã¿ãã¯ã¯ãã³æ¥çš®ãæ¯æããŠãããšè§£éãããã»ã©ã§ããã
ããã§ã€ãã»ãããªã²ã¹ãšã¢ã³ãã©ãŒãã¯ã2020幎ãã2023幎ã«ãããŠãã©ãžã«ã§COVID-19ãšèšºæãããå šæ£è ã察象ãšãããå¥ã®åºç¯ãªç ç©¶ãè¡ã£ãã
圌ãã®çµè«ã¯æé²ã«èŠçŽãããŠããïŒ
ãCOVID-19å ç«ã®äºé²å¹æã¯ãæåã®çç¶ãã1幎åŸãŸã§èгå¯ãããã1幎åŸã«ã¯å¹æã¯é転ããã¯ã¯ãã³æ¥çš®è ã®æ»äº¡ãªã¹ã¯ãå¢å ããã
ããã¯å³1ã«ç€ºãããŠãããX軞ã¯ç忥æ°ã§ããïŒ

ãã®æèã§ã¯ç°äŸãªããšã ããèè ãã¡ãããŒã¿ãæ£ç¢ºã«åæ ããçµè«ã«éããããšãç¥çŠããªããã°ãªããªããéåžžã¯é¡é¢éãã«åãå ¥ããããã¯ã¯ãã³æ¥çš®ã«é¢ãããªãŒãœããã¯ã¹ãªçµè«ã«éããè«æã§ã¯æ±ºããŠèµ·ãããªãããšã§ããã
åºçãã€ã¢ã¹ã¯èå»¶ããŠãããèåãªæ»èªè ãã¡ã¯ããŒã«è«æãã©ãæ±ãã®ã ãããïŒãã®2ã€ã®è«æã®éåœãéèŠãªè©Šéç³ãšãªãã ãããçŸåšã®åœ¢ã§ã¯ããã©ãžã«ç ç©¶ã¯æ€åãããããŒã«è«æã¯åçããããšäºæ³ãããã
è¯å®çãªçµè«ã«éããç ç©¶ã¯ãéžæãããæéïŒã±ãŒã¹ã«ãŠã³ããŠã£ã³ããŠãã€ã¢ã¹ãšåŒã°ãããã®ã®ããªãšãŒã·ã§ã³ïŒã«åºã¥ãããã¢ããªã³ã°ã«åºã¥ããã®ã©ã¡ããã§ããã
äŸãã°ãChristopher Ruhmã«ããç±³åœåå·ã®æšªæçç ç©¶ã¯ãå·ã®COVID-19é¢é£èŠå¶ïŒéè¬ç©ä»å ¥ãšã¯ã¯ãã³çŸ©ååïŒãç±³åœå ã®ãã³ãããã¯æ»äº¡è æ°ã«åœ±é¿ãäžãããã©ããã確èªããããšãç®çãšãããã®ã§ããã
ãã®ç ç©¶ã¯ç±³åœå šäœæ°ã®ããŒã¿ã«åºã¥ããŠããããã®æå³ã§ã¯å æ¬çã§ãããRuhmæ°ã¯æ¬¡ã®ããã«çµè«ããŠããïŒ
ããã®æšªæç ç©¶ã¯ãCOVID-19ã®å³æ Œãªå¶éããã°ã«ãŒããšããŠããã³ãããã¯æ»äº¡çã®å€§å¹ ãªæžå°ã«é¢é£ããŠãããè¡åã®å€åãéèŠãªèª¬æã¡ã«ããºã ãšããŠæ©èœããŠããããšã瀺ããŠãããã
ããããæ±ºå®çãªã®ã¯ãã®æéã§ããïŒ ãäž»èŠèª¿æ»æéã¯2020幎7æãã2022幎6æãŸã§ã®2幎éã§ãããã
ãã以åã®æã¯ã©ããªã®ãïŒCOVID-19ã«ããæ»äº¡çã®æåã®æ³¢ã¯åæ±éšã®å·ãçŽæãã調æ»å¯Ÿè±¡ããæŒããŠããããã ã
ãã®åŸã®æ³¢ã¯åéšãšè¥¿éšã®å·ã襲ã£ãã®ã§ããã®æéã®è¶ éæ»äº¡çã®å€åã¯å°ççèŠå ã«å€§ãã圱é¿ãããã
ããã¯èª¿æ»æéã®å³2Cã«æããã§ããïŒ


ä»å ¥ãããå³ãããªãå·ã§ã¯ã2021幎7æä»¥é1ã«æã»ã©æ»äº¡çãé«ãã£ããèª¿æ»æéãçµäºããããã«ã¯ããªã¬ã³ãžè²ã®ç·ã¯åã³äžæããŠããã
COVID-19äºé²æ¥çš®ã®äºé²å¹æã¯ãæåã®çç¶ãåºãŠãã1幎åŸãŸã§ã¯èгå¯ããããã1幎åŸã«ã¯å¹æãé転ããããšãæããã«ãããã©ãžã«ã®ç ç©¶ãæãåºããŠã»ããã
KuhbandnerãšReitznerã«ããã2020-2022幎ã®ãã€ãã«ãããéå°æ»äº¡çã®æšå®ããèããŠã¿ãããèè ã¯ããæ»äº¡çå¢å ã®æšå®å€ãè§£éããéã«ã¯ãã¢ãã«ãšãã©ã¡ãŒã¿ãŒã®éžæã«æ³šæããªããã°ãªããªã ããšæ£ããèªããŠããã
è«æã®åŸåã§ã圌ãã¯2020幎3æä»¥éã®éå°æ»äº¡çãšã¯ã¯ãã³æ¥çš®ãæç³»åã§å¯Ÿå¿ãããŠãããã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ã®ååŸã«æ»äº¡çã®ããŒã¯ããããèª¿æ»æéã®çµç€ã«å€§ããäžæããŠããããšããããïŒ

çµè«ã¯ããã ïŒ
ã2020å¹Žã®æ»äº¡è æ°ã¯äºæ³ã«æ¥µããŠè¿ãã£ããã2021å¹Žã®æ»äº¡è æ°ã¯çµéšçæšæºåå·®ã®2åã®ãªãŒããŒã§äºæ³ãã¯ããã«äžåãã2022幎ã«ã¯çµéšçæšæºåå·®ã®4å以äžã§ãã£ãã
ããã¯ã¯ã¯ãã³æ¥çš®ãã£ã³ããŒã³ã®åå©ãšè§£éããããšã¯ã§ããªããéå°æ»äº¡ãé²ãã¯ãã®ã¯ã¯ãã³æ¥çš®ããããªããªãã£ãã®ã§ããã
Alessandriaãã¯ããA Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian ProvinceãïŒPescaraïŒãçºè¡šããæ¢åã®ããŒã¿ã»ããã®ååæãè¡ããæ¯éå£ãåäžã®ææšæ¥ïŒ2021幎1æ1æ¥ïŒã«åãããããšã§äžæ» æéã®ãã€ã¢ã¹ãè£æ£ããã
ãã®çµæ
ã1åã2åã3/4åæ¥çš®ã®ã¯ã¯ãã³æ¥çš®è ãšæªæ¥çš®è ãšã®åå€éè§£æã«ãããå šæ»å æ»äº¡ãã¶ãŒãæ¯ã¯ããããã0.88ã1.23ã1.21ã§ãã£ããå€å€éè§£æã§ã¯2.40ã1.98ã0.99ã§ãã£ãã
3åç®ãš4åç®ã®ãã¶ãŒãæ¯ã¯ãæè¿ã®ãã®ã§ããããäœããªãããšãå€ãããã©ãžã«ã®ç ç©¶ã§èŠãããããã«ãæåã®æ¹åã¯åŸã«é転ããã
Alessandriaãã¯ã芳å¯ç ç©¶ã«ãããŠãã¯ã¯ãã³æ¥çš®åŸ10ïœ14æ¥ç®ã®çµæãã¯ã¯ãã³çŸ€ããé€å€ããå¯Ÿç §çŸ€ã«ã¯åæ§ã®ãã€ã¢ã¹ããããªããšãããç¹æ®ãªã¿ã€ãã®çäŸã«ãŠã³ããŠã£ã³ããŠãã€ã¢ã¹ãå«ããã¯ã¯ãã³æ¥çš®ç ç©¶ã«åœ±é¿ãäžãããæ§ã ãªã¿ã€ãã®ãã€ã¢ã¹ã«ã€ããŠæ€èšããå ±åãçµããã
Fungãã«ããã°ããã®ãã€ã¢ã¹ã«åºã¥ãã°ãããŸã£ãã广ã®ãªãã¯ã¯ãã³ãå®è³ªçã«æå¹ã§ããããã«èŠãããïŒãã¡ã€ã¶ãŒç€Ÿã®ç¬¬IIIçžã©ã³ãã å詊éšã®ããŒã¿ãçšããŠåœŒããèšç®ããäŸã§ã¯ã48ïŒ ãæå¹ã§ããïŒã
ç§ã®ç·èª¬ã®ä»äžããããŠããéã«ãAnnals of Internal Medicineèªã¯Ioannouãã® ãEffectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up ããçºè¡šããã
ãã®ç ç©¶ã¯ãXBB.1.5ã¯ã¯ãã³æ¥çš®è ãšã¯ã¯ãã³æªæ¥çš®è ããããã³ã°ãããå¯Ÿç §èšåºè©Šéšãæš¡å£ããããšãããã®ã§ãããçµè«ã¯åºæ¿çãªãã®ã§ã¯ãªãïŒ
ãSARS-CoV-2ã«é¢é£ããæ»äº¡ã«å¯Ÿããã¯ã¯ãã³ã®æå¹æ§ã¯ã60æ¥åŸã90æ¥åŸã120æ¥åŸã®è¿œè·¡èª¿æ»ã§åŸã ã«äœäžãïŒãããã54.24ïŒ ã44.33ïŒ ã30.26ïŒ ïŒã远跡調æ»çµäºãŸã§å»¶é·ãããšããã«äœäžããïŒ26.61ïŒ ïŒã
ããã¯å³3ã«è¡šãããŠããïŒ

ã€ãŸããçäŸæ°ã«ãŠã³ãã®ãŠã£ã³ããŠã¯10æ¥ç®ãã210æ¥ç®ãŸã§ãšæããããçªã®å€ã§äœãèµ·ãããã¯ããããªããçäŸæ°ã«ãŠã³ãã®çªã®ãã€ã¢ã¹ãèæ ®ããŠãæªãçµæãèšé²ãããã®ã§ããã°ãçŸå®ã¯ãã£ãšæªãã¯ãã§ããã
ããããã¯èгå¯ç ç©¶ã®äžéšãã¬ãã¥ãŒããŠãããæè¯ã®äŸã§ã¯ãã¯ã¯ãã³æ¥çš®ã«ããå®è³ªçãªå©ç¹ã¯ãªããææªã®ã·ããªãªã§ã¯ãã¯ã¯ãã³æ¥çš®çŸ€ã§æ»äº¡ãå€ãã
ãŸãããã³ãããã¯æéäžã®æ»äº¡çãäºæ³æ»äº¡çãšæ¯èŒããåäºå®ç ç©¶ãæ°å€ãè¡ãããŠããã
Watsonãã«ããæåã®ç ç©¶ã§ã¯ã185ã«åœã§ã¯ã¯ãã³æ¥çš®ã®å幎床ã«1,440äžäººã®COVID-19ã«ããæ»äº¡ãåé¿ããããšæšå®ãããè¶ éæ»äº¡ãææšãšãããš2,000äžäººè¿ãã«ãŸã§å¢å ããã
ããã¯é©ç°çãªæ°åã§ãããäžè¬ã®äººã ã®æ³ååã«äžŠã ãªãã¬åœ±é¿ãäžããã¡ãã£ã¢ã§ãé »ç¹ã«èšåãããŠããããã®æ°åã¯Ioannidisãã«ããã¬ãã¥ãŒã§æŽæ°ãããŠããã
é©ãããšã§ã¯ãªãããCOVID-19ã¯ã¯ãã³æ¥çš®ã®å¹æãèããŠããŠããããšãèæ ®ãããšããã®èè ãã¡ã¯250äžäººä»¥äžã®åœãæã£ããšãããããä¿å®çãªæ°åãåºããŠããã
Ioannidisãã¯ãªãã¯ãã³åã®VEã75ïŒ ããªãã¯ãã³æéäžã®VEã50ïŒ ãšããŠããã
ãããã¯ãããããçåæ§ææçã«å¯Ÿããèšåºè©Šéšã§èªããããVEã«åºã¥ããŠãããšæãããããæ»äº¡çåé¿ã®æšå®å€ã«çµéšçæ ¹æ ãããããšã¯æããã§ã¯ãªãã
ã¢ããªã³ã°ã¯ãšããã³ã¹ã§ã¯ãªãããšããã³ã¹ã«åºã¥ãå»çã®éå±€ãã©ãããã«ã¯ç»å Žããªããæ²»çã广çã§ãããšä»®å®ããããéå£ã«å¯Ÿãããã®å¹æãèšç®ããã°ãå¿ ç¶çã«ãæ²»çã广çã§ãããããšããããïŒä»®èª¬ã¯å蚌å¯èœã§ã¯ãªããæšè«ã¯åŸªç°ããã
COVID-19ã®ãã³ãããã¯ã¯ãååœæ¿åºããããã¯ã«é¥ããç·æ¥å¯Ÿçããšããããããã®æ¥µç«¯ãªè åšã¯ãæ¬æ°ãªå¯Ÿçãªãã«æ¥µããŠé«ãã¬ãã«ã®æ»è ãåºããšä»®å®ããã¢ããªã³ã°ã«ãã£ãŠäœãåºããããã®ã§ããã
ãã³ãããã¢ãçºçããäºåºŠãšç¹°ãè¿ãããŠã¯ãªããªããé¡ãã°ãæ£çµ±æŽŸã¯çŸåšããã®ãããªæ¶ç©ºã®ã¬ãã«ã®æ»äº¡ãèµ·ãããªãã£ãã®ã¯å¯Ÿçã®ãããã§ããããšã瀺ãããšããŠããã
ãããã®ç ç©¶ãããäžæçãªæ»äº¡çã«é¢ãã3ã€ã®ã·ããªãªãæµ®ãã³äžãã£ãŠããïŒ
VE = 50-70
VEïŒ0
VEã¯ãã€ãã¹
æåã®ã·ããªãªã«ã¯å®èšŒç蚌æ ãäžè¶³ããŠãããä»ã®ã·ããªãªã¯åãå ¥ããããªããã·ããªãª2ã¯å®¹èªã§ããªãããªããªããæçæ§ããªããå¯äœçšã«ãããããå¯èœæ§ãããã®ã§ããã°ã人ã ã«æ²»çãæœãããšã¯ã§ããªãããCOVID-19ã¯ã¯ãã³ã®å¯äœçšã¯ãFraimanãã瀺ããããã«ãç°åžžã«é«ãããã§ããã
ç£çŠã«ããæªåœ±é¿ãèç©ããç¶ããŠãããç¹ã«è¥è ã®ã¡ã³ã¿ã«ãã«ã¹ãæè²æ°Žæºã«åœ±é¿ãåãŒããŠããã
ãã§ã«ã¯ããšãŽã¡ãŒã·ã¥ããŒã«ããã°ã次ã®ããã«ãªãïŒ
ãããã¯ããŠã³ã¯ãããã¯ããŠã³ã®ãªãå°åãšæ¯èŒããŠãããã¯ããŠã³ã®ããå°åã®ã¡ã³ã¿ã«ãã«ã¹æœèšã®å©çšãææãã€å æçã«å¢å ããããç¹ã«ãããã¯ããŠã³ã®ããå°åã§ã¯ããªãœãŒã¹ã®å©çšã18ïŒ å¢å ããã®ã«å¯Ÿããããã¯ããŠã³ã®ãªãå°åã§ã¯1ïŒ æžå°ããã
ããŸãã女æ§ã®éå£ã¯ã粟ç¥çå¥åº·ã«å¯ŸããŠãã倧ããªããã¯ããŠã³ã®åœ±é¿ã«ãããããŠããããããã¯é害ã®èšºæãšæ·±å»ãªã¹ãã¬ã¹ãžã®åå¿ã¯ãããã¯ããŠã³ã«ãã£ãŠææã«å¢å ãããã¡ã³ã¿ã«ãã«ã¹ã¯ããã³ãããã¯ã®ååšãã®ãã®ããããããã¯ããŠã³ã«å¯ŸããŠããææã§ãã£ããã
ãã³ãããã¯æŠç¥ã¯å²äžæå€§ã®å ¬è¡è¡çå®éšã§ãã£ããç§ã¯ããç ç©¶å«çå§å¡äŒã®å§å¡é·ãšããŠãæ£å³ã®å©çããŒãããã以äžã«ãªããããªææ¡ã«ã¯å察祚ãæãããå©çããªã¹ã¯ãæããã«äžåããªããã°ãªããªãã
ç§ã®æ é·ã§ãããã¯ããªã¢å·ã¡ã«ãã«ã³ã§ã¯ãå šäœæ°ã262æ¥éèªå® åŸ æ©ãšãªã£ãããã®åŸããã¹ãŠã®ãå¿ èŠäžå¯æ¬ ãªåŽåè ãïŒãããŠã»ãŒãã¹ãŠã®åŽåè ãå¿ èŠäžå¯æ¬ ã§ããããšã倿ããïŒã«å³ããã¯ã¯ãã³æ¥çš®ã®çŸ©åã課ãããæªæ¥çš®è ã¯å ¬å ±ã®å Žããç· ãåºãããå¥åº·äžã®å±éºãšã¿ãªãããã
ä»ã®å³¶åœãšåæ§ããªãŒã¹ãã©ãªã¢ãåœå¢ãééããŠããæéã¯ããªãããŸããã£ãããå£®å€§ãªæŠç¥ã¯ããŸããããªãã£ããäžéçãªéè¬åä»å ¥æéã®åŸãã¯ã¯ãã³æ¥çš®ãå°æ¥ããŠããæ³å®ããããããªéå°æ»äº¡ã¯é²ããªãã£ãã®ã§ããïŒ

æ¬è³ªçãªååã¯ãå ¬è¡è¡çäžã®æªçœ®ãããããå人ã®èªç±ã®äŸµå®³ãæ·±å»ã§ããã°ããã»ã©ããã®æå¹æ§ã«é¢ãã確åºãã蚌æ ãå¿ èŠã ãšããããšã ã
æ¿åºã¯ãèªåãã¡ã®ä»å ¥ãçè«çã«ã¯ããŸããããããããªããšèããå人ã®èªç±ãèžã¿ã«ãããããªããšããã£ãŠã¯ãªããªãã
åæïŒBrownstone Institute
ãã€ã±ã«ã»ãã ãªã³ãœã³ã¯ãé«çæè²ã®ã¬ããã³ã¹ãšè³ªã«é¢ããã³ã³ãµã«ã¿ã³ãã§ããã以åã¯ããªãŒã¹ãã©ãªã¢ã®é«çæè²è³ªã»åºæºæ©æ§ïŒTertiary Education Quality and Standards AgencyïŒã®è³ªä¿èšŒã°ã«ãŒãã®ãã£ã¬ã¯ã¿ãŒãåããé«çæè²ã®åºæºå€ã«ç §ãããŠãç»é²ããããã¹ãŠã®é«çæè²æäŸè ïŒãªãŒã¹ãã©ãªã¢ã®ãã¹ãŠã®å€§åŠãå«ãïŒã®è©äŸ¡ãè¡ãããŒã ãçããŠããããã以åã®20幎éã¯ããªãŒã¹ãã©ãªã¢ã®å€§åŠã§èŠè·ãæŽä»»ãã¢ãžã¢å€ªå¹³æŽå°åã®å€§åŠã®ãªãã·ã§ã¢ã¬ãã¥ãŒã®å°éå®¶ããã«ã¡ã³ããŒãåããããªãŒã¹ãã©ãªã¢ã»ã¬ããã³ã¹åäŒããã³ïŒåœéïŒãã£ãŒã¿ãŒãã»ã¬ããã³ã¹åäŒã®ãã§ããŒã